Innate Pharma Sa Stock Price, News & Analysis

Innate Pharma announced FDA clearance of its IND application for IPH4502, a novel topoisomerase I inhibitor antibody drug conjugate (ADC) targeting Nectin-4 in solid tumors. The company plans to initiate a Phase 1 clinical study in the coming months. The study will be an open-label, multi-center trial assessing the safety, tolerability, and preliminary efficacy of IPH4502 as a single agent in advanced solid tumors known to express Nectin-4, including urothelial carcinoma, non-small cell lung, breast, ovarian, gastric and colorectal cancers.

The study will include a Part 1 Dose Escalation and a Part 2 Dose Optimization. This marks Innate's first ADC program to enter clinical trials, representing a significant milestone for the company.

Innate Pharma reported its H1 2024 business update and financial results. Key highlights include:

- Positive Phase 2 results for lacutamab in mycosis fungoides presented at ASCO 2024

- NK-Cell engager SAR443579/IPH6101 advanced to Phase 2 and initiated front-line AML Phase 1/2 combination study

- IPH45 ADC progressing towards Phase 1 in H2 2024

- Cash position of €102.1 million as of June 30, 2024

- Revenue decreased to €12.3 million in H1 2024 from €40.2 million in H1 2023

- Operating expenses decreased slightly to €38.7 million in H1 2024 from €40.6 million in H1 2023

- R&D expenses decreased to €29.1 million in H1 2024 from €31.5 million in H1 2023

The company continues to advance its pipeline and maintains a cash runway until end of 2025.

Innate Pharma SA announced interim results from AstraZeneca's NeoCOAST-2 Phase 2 study presented at the 2024 World Conference on Lung Cancer. The study evaluates neoadjuvant durvalumab alone or combined with novel agents and chemotherapy in resectable, early-stage non-small cell lung cancer (NSCLC). Preliminary data from Arm 2 showed that monalizumab added to durvalumab plus platinum-based chemotherapy induced a pathological complete response rate of 26.7% and a major pathological response rate of 53.3%, numerically higher than the approved regimen. The treatment demonstrated a manageable safety profile with no impact on surgical rate. Innate Pharma's Chief Medical Officer expressed excitement about the potential of extending durvalumab's clinical benefit with monalizumab in NSCLC patients.

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) has announced a conference call and webcast scheduled for Thursday, September 12, 2024, at 2 p.m. CEST / 8 a.m. EDT. The event will provide an update on the company's business progress during the first half of 2024. Key participants will include CEO Hervé Brailly, CMO Sonia Quaratino, COO Yannis Morel, CFO Frédéric Lombard, and EVP and President of US Operations Arvind Sood.

Investors and interested parties can join the live webcast or participate via telephone. A replay of the webcast will be available on the company's website for 90 days following the event. This announcement suggests that Innate Pharma is preparing to share important financial results and business updates with its stakeholders.

Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 10, 2024, in New York, United States. Arvind Sood, EVP and President of US Operations, will represent the company at this investor conference. This participation provides Innate Pharma with an opportunity to engage with investors and showcase its business developments and potential investment prospects.

Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) has announced its participation in the upcoming BTIG Virtual Biotechnology Conference, scheduled for August 5-6, 2024. The company will be represented by key executives, including Yannis Morel, EVP and Chief Operating Officer, and Arvind Sood, EVP and President of US Operations.

This virtual conference provides an opportunity for Innate Pharma to engage with investors and showcase its latest developments in the biotechnology sector. The company's presence at such events is important for maintaining investor relations and potentially attracting new investment opportunities.

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) has released its total number of shares outstanding and voting rights as of July 10, 2024. The company's share structure includes 80,969,357 ordinary shares, 6,494 Preferred Shares 2016, and 7,581 Preferred Shares 2017. The total number of theoretical voting rights stands at 81,724,597, while the total number of exercisable voting rights is 81,706,022. This disclosure is in compliance with French regulatory requirements and aims to keep the market adequately informed about the company's share structure and voting rights distribution.

Innate Pharma SA reported its total number of shares and voting rights as of June 10, 2024.

The company has 80,967,407 ordinary shares, 6,509 Preferred Shares 2016, and 7,581 Preferred Shares 2017.

The total number of theoretical voting rights stands at 81,724,597, while the number of exercisable voting rights is 81,706,022.

This information is disclosed to comply with regulations by the AMF, ensuring market transparency.

Innate Pharma's Phase 1/2 trial of SAR443579 (SAR’579), developed with Sanofi, continues to show promising results for treating relapsed/refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), and high-risk myelodysplasia (HR-MDS). The clinical trial results, presented at the European Hematology Association 2024 Congress, highlight 5 complete remissions at a 1 mg/kg dose, with 3 patients achieving durable CR over 10 months. SAR’579 has an FDA Fast Track Designation for acute myeloid leukemia and has shown a favorable safety profile at doses up to 6 mg/kg weekly. The study has now progressed to Phase 2, focusing on further demonstrating the efficacy of this NK cell engager.